Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models

Cancer Research

Volumn 60, Issue 13, 2000, Pages 3389-3393

  Tardi, Paul ^b   Choice, Edward ^b   Masin, Dana ^b   Redelmeier, Thomas ^c   Bally, Marcel ^b   Madden, Thomas D ^a  

^a Inex Pharmaceuticals Corporation   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c JACK BELL RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; TOPOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; ENCAPSULATION; FEMALE; HUMAN; HYDROLYSIS; LIVER METASTASIS; MOUSE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; SURVIVAL TIME; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG CARRIERS; FEMALE; HUMANS; LEUKEMIA L1210; LIPOSOMES; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, INBRED STRAINS; MICE, SCID; SURVIVAL RATE; TOPOTECAN; TRANSPLANTATION, HETEROLOGOUS;

EID: 0034234238     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. D'Arpa, P., and Liu, L. F. Topoisomerase-targeted anticancer drugs. Biochim. Biophys. Acta, 989: 163-177, 1989.
2. Grochow, L. B., Rowinsky, E. K., Johnson, R., Ludeman, S., Kaufmann, S. H., McCabe, F. L., Smith, B. R., Hurowitz, L., DeLisa, A., Donehower, R. C., and Noe, D. A. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab. Dispos., 20: 706-713, 1992.
3. Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., and Jain, R. K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res., 55: 3752-3756, 1995.
4. Gabizon, A., Goren, D., Cohen, R., and Barenholz, Y. Development of liposomal anthracyclines: from basics to clinical applications. J. Control Release, 53: 275-279, 1998.
5. Webb, M. S. Harasym, T. O., Masin, D., Bally, M. B., and Mayer, L. D. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetics and therapeutic properties of vincristine in murine and human tumor models. Br. J. Cancer, 72: 896-904, 1995.
6. Chang, C. W., Barber, L., Ouyang, C., Masin, D., Bally, M. B., and Madden, T. D. Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice. Br J. Cancer, 75: 169-177, 1997.
7. Lim, H., Masin, D., Madden, T. D., and Bally, M. B. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. J. Pharmacol. Exp. Ther., 281: 566-573, 1997.
8. Burke, T. G., Mishra, A. K., Wani, M. C., and Wall, M. E. Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry, 32: 5352-5364, 1993.
9. Ouyang, C., Choice, E., Holland, J., Meloche, M., and Madden, T. D. Liposomal cyclosporine: characterization of drug incorporation and interbilayer exchange. Transplantation, 60: 999-1006, 1995.
10. Choice, E., Masin, D., Bally, M. B., Meloche, M., and Madden, T. D. Liposomal cyclosporine: comparison of drug and lipid carrier pharmacokinetics and biodistribution. Transplantation, 60, 1006-1011, 1995.
11. Hope, M. J., Bally, M. B., Webb, G., and Cullis, P. R. Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim. Biophys. Acta, 812: 55-65, 1985.
12. Mayer, L. D., Hope, M. J., Cullis, P. R., and Janoff, A. S. Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles. Biochim. Biophys. Acta, 817: 193-196, 1986.
13. Fenske, D. B., Wong, K. F., Maurer, E., Maurer, N., Leenhouts, J. M., Boman, N., Amankwa, L., and Cullis, P. R. Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients. Biochim. Biophys. Acta, 1414: 188-204, 1998.
14. Pick, U. Liposomes with a large trapping capacity prepared by freezing and thawing sonicated phospholipid mixtures. Arch. Biochem. Biophys., 212: 186-194, 1981.
15. 3H]cholesteryl oleyl ether in cultured fibroblasts and intact rat. FEBS Lett., 111: 104-106, 1980.
16. Leonessa, F., Green, D., Licht, T., Wright, A., Wingate-Legette, K., Lippman, J., Gottesman, M. M., and Clarke, R. MDA435/LCC6 and MDA435/LCC6MDRI: ascites models of human breast cancer. Br. J. Cancer. 73: 154-161, 1996.
17. Warner, D. L., and Burke, T. G. Simple and versatile high-performance chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. J. Chromatogr. B. 691: 161-171, 1997.
18. Allen, T. M., and Stuart, D. D. Liposome pharmacokinetics: classical, sterically stabilized, cationic liposomes and immunoliposomes. In: A. S. Janoff (ed.), Liposomes: Rational Design, pp. 63-87. New York: Marcel Dekkar, 1999.
19. Mi, Z., and Burke, T. G. Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry, 33: 10325-10336, 1994.
20. Mayer, L. D., Cullis, P. R., and Bally, M. B. Designing therapeutically optimized liposomal anticancer delivery systems: lessons from conventional liposomes. In: D. Lasic and D. Papahadjopoulos (eds.), Medical Applications of Liposomes, pp. 231-257. Amsterdam: Elsevier Science, 1998.
21. Boman, N. L., Bally, M. B., Cullis, P. R., Mayer, L. D., and Webb, M. S. Encapsulation of vincristine in liposomes reduces toxicity and improves antitumor efficacy. J. Liposome Res., 5. 523-541, 1995.
22. Burke, T. G., and Gao, X. Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine. J. Pharm. Sci., 83: 967-969, 1994.
23. Yuan, F., Leunig, M., Huang, S. K., Berk, D., Papahadjopoulos, D., and Jain, R. K. Micro-vascular and interstitial penetration of sterically stabilized (Stealth) liposomes in a human tumor xenograft. Cancer Res., 54: 3352-3356, 1994.
24. Chonn, A., Semple, S. C., and Cullis, P. R. Separation of large unilamellar liposomes from blood components by a spin column procedure: towards identifying plasma proteins which mediate liposome clearance in vivo. Biochim. Biophys. Acta. 1070: 215-222, 1991.
25. Bally, M. B., Nayar, R., Masin, D., Hope, M. J., Cullis, P. R., and Mayer, L. D. Liposomes with entrapped doxorubicin exhibit extended blood residency times. Biochim. Biophys. Acta, 1023: 133-139, 1990.
26. Horwitz, S. B., and Horwitz, M. S. Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res., 33: 2834-2836, 1973.
27. Recondo, G., Abbruzzese, J., Newman, B., Newman, R., Kuhn, J., von Hoff, D., Gartiez, D., and Raber, M. A Phase 1 trial of topotecan (TOPO) administered by a 24 hour infusion. Proc. Am. Assoc. Cancer Res., 32: 206, 1991.
28. Slichenmyer, W. J., Rowinsky, E. K.. Donehower, R. C., and Kaufmann, S. H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst., 85: 271-291, 1993.
29. McCabe, F. L., and Johnson, R. K. Comparative activity of oral and parenteral topotecan in murine tumor models: efficacy of oral topotecan. Cancer Invest., 12: 308-313, 1994.
30. Kollmannsberger, C., Mross, K., Jakob, A., Kanz, L., and Bokemeyer, C. Topotecan - a novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology, 56: 1-12, 1999.